{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:00:24Z","timestamp":1791216024945,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clinthera.2020.10.007","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T08:51:38Z","timestamp":1605603098000},"page":"2321-2330.e0","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study"],"prefix":"10.1016","volume":"42","author":[{"given":"Sandro","family":"Feriozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3372-7850","authenticated-orcid":false,"given":"Ales","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Kalampoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Gurevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.10.007_bib1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.clinthera.2020.10.007_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2020.10.007_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment","volume":"10","author":"Kampmann","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2020.10.007_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","article-title":"The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders","volume":"16","author":"Wyatt","year":"2012","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.clinthera.2020.10.007_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2020.10.007_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2020.10.007_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: a key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2020.10.007_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.clinthera.2020.10.007_bib9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings","volume":"57","author":"Devereux","year":"1986","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2020.10.007_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2020.10.007_bib11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/0735-1097(94)00540-7","article-title":"Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk","volume":"25","author":"de Simone","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2020.10.007_bib12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2010.03.026","article-title":"Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) study equations for estimating GFR levels above 60 mL\/min\/1.73 m2","volume":"56","author":"Stevens","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2020.10.007_bib13","first-page":"1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.clinthera.2020.10.007_bib14","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1093\/ndt\/gfq108","article-title":"The value of estimated GFR in comparison to measured GFR for the assessment of renal function in adult patients with Fabry disease","volume":"25","author":"Rombach","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2020.10.007_bib15","first-page":"2090","article-title":"Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease","volume":"32","author":"Lenders","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2020.10.007_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2020.10.007_bib17","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2020.10.007_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/heartjnl-2014-306278","article-title":"Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease","volume":"101","author":"Talbot","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2020.10.007_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.clinthera.2020.10.007_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2020.10.007_bib21","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2020.10.007_bib22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2004030203","article-title":"Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999","volume":"16","author":"Foley","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2020.10.007_bib23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2020.10.007_bib24","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts","volume":"79","author":"van der Velde","year":"2011","journal-title":"Kidney Int"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820304756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820304756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:53:37Z","timestamp":1758963217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820304756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0149291820304756"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.10.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Takeda Pharmaceutical Company. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}